Literature DB >> 3259692

Prevalence and significance of methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis.

B Boxerbaum1, M R Jacobs, R L Cechner.   

Abstract

Recent reports indicate that methicillin-resistant Staphylococcus aureus (MRSA) may be emerging as a significant pediatric nosocomial pathogen. Children with cystic fibrosis (CF) pulmonary disease are subject to many of the risk factors for MRSA colonization and/or infection. We retrospectively investigated the prevalence and significance of MRSA from sputum and throat cultures in 452 patients with CF followed during 1986. No MRSA had been isolated during 1984 or 1985. Although S. aureus was isolated from 212 patients (47%) in 1986, only 14 (3%) showed MRSA. The MRSA strains had 11 different antimicrobial susceptibility patterns. Neither age, clinical condition, nor recent prior hospitalization correlated with MRSA acquisition. Acquisition did not appear to directly affect the course of the pulmonary disease in these patients even though no patient received any treatment for their MRSA. The prevalence of MRSA is low, although patients with CF are subject to many risk factors. MRSA appears to be mainly community-acquired and to represent colonization rather than infection. However, the potential for nosocomial MRSA infection is present, and vigilance is required in monitoring any changes in frequency of isolation or infection with these organisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259692     DOI: 10.1002/ppul.1950040307

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  10 in total

Review 1.  Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.

Authors:  J R Govan
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis.

Authors:  L S Miall; N T McGinley; K G Brownlee; S P Conway
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

4.  Is Methicillin-Resistant Staphylococcus Aureus Colonization Associated with Worse Outcomes in COPD Hospitalizations?

Authors:  Erin R Narewski; Victor Kim; Nathaniel Marchetti; Michael R Jacobs; Gerard J Criner
Journal:  Chronic Obstr Pulm Dis       Date:  2015

5.  Pharmacokinetics of vancomycin in adult cystic fibrosis patients.

Authors:  R A Pleasants; E L Michalets; D M Williams; W M Samuelson; J R Rehm; M R Knowles
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Eradication of methicillin-resistant Staphylococcus aureus from the lower respiratory tract of patients with cystic fibrosis.

Authors:  D R Burdge; E Nakielna; M Noble
Journal:  Can J Infect Dis       Date:  1995-03

7.  Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients.

Authors:  V Cafiso; T Bertuccio; D Spina; F Campanile; D Bongiorno; M Santagati; A Sciacca; C Sciuto; S Stefani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-04       Impact factor: 3.267

8.  Antimicrobial resistance of Staphylococcus from otorrhea in chronic suppurative otitis media and comparison with results of all isolated Staphylococci.

Authors:  D C Park; S K Lee; C I Cha; S-O Lee; M S Lee; S G Yeo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-26       Impact factor: 3.267

Review 9.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 10.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.